Japanese Sanofi To Quit Marketing Agreements For Nine Drugs (Japan)
This article was originally published in PharmAsia News
Executive SummarySanofi-Aventis KK, the French drug maker's Japanese unit, has decided to end its marketing partnerships and handle its own sales of flagship drugs in Japan. The firm's president said the change in strategy is part of its effort to double the 2005 Japanese sales level next year. The marketing partnerships include Chugai Pharmaceutical, handling seven drugs, which is to be canceled at the end of this year. Other partnerships are with Amoban for a sleep-disorder treatment, and Menamin for an anti-inflammatory painkiller, and they are to be ended in January. (Click here for more - may require subscription
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.